Research programme: rearranged during Transfection kinase inhibitors - Tyra Biosciences
Alternative Names: RET - Tyra Biosciences; RET inhibitors - Tyra Biosciences; RET ProgramLatest Information Update: 16 Mar 2022
At a glance
- Originator Tyra Biosciences
- Class Antineoplastics; Small molecules
- Mechanism of Action Proto-oncogene protein c-ret inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Lung cancer; Thyroid cancer